Our studies on creation of functional organic compounds and their applications, have focused on three areas, namely, (A) organic chemical studies on VD (vitamin D) analogues, (B) studies on solitary wasp venoms, and (C) studies on functional building blocks for organic synthesis. In theˆrst area, several novel and important vitamin D analogues were synthesized and biologically evaluated, and their high VDR (vitamin D receptor) binding a‹nities were discussed on the basis of conformational analysis and docking study by Molecular Mechanics Calculation to the LBD (ligand binding domain) of VDR: These compounds include 24,24-di‰uoro-1a,25-dihydroxy-VD 3 (2) (an antimetabolism agent, theˆrst VD analogue having higher potency than the natural hormone (1)), 2a-methyl-1a,25-dihydroxy-VD 3 (42b) (theˆrst A-ring-modiˆed VD analogue exhibiting stronger VDR a‹nity than 1) and its 20-epimer (43b) (a VD analogue having a highest HL-60 cell diŠerentiation inducing activity with a relatively low calcemic eŠect), and 2a-(v-hydroxypropyl)-1a,25-dihydroxy-VD 3 (exceptionally high calcemic eŠect). In the second area, we isolated and determined the structure of pompilidotoxins (76, 77), novel peptide neurotoxins in solitary wasp venoms. In the third area, we created furan-fused 3-sulfolene, 4H, 6H-thieno ［3,4-c］ -furan 5,5-dioxide and pyrrole-fused 3-sulfolene (96), 3,5-dihydro-1H-thieno ［3,4-c］ pyrrole 2,2-dioxide (125), and studied their inter-and intramolecular Diels-Alder reactions.
a) DDQ in dioxane, re‰ux, b) t-BuOK in DMSO, 15°C, then H2O, c) Ca (BH 4 ) 2, EtOH-MeOH, -10°C, d) Ac2O, pyridine, e) NBS in hexane-benzene, re‰., f) collidine in xylene, re‰., g) 4-phenyl-1,2,4,-triazoline-3,5-dione, h) NaOH in EtOH, i) m-CPBA in CHCl3, j) LAH in THF, re‰., k) hn in ether, l) EtOH, r. t. 
エン反応にとり生じた 2 種の過酸化水素誘導体 （36） 16, 17) 合成は，鎖状の A 環前駆体 enyne (40）と側鎖を a) The potency of 1 is normalized to 100. b) Binding a‹nity to bovine thymus VDR. c) Binding a‹nity to calf serum VD binding protein. d ) Cell diŠerentiation was assessed in terms of NBT reductivity. e) lncreasing eŠect on serum calcium level in normal rats. f ) Not Tested.
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Vol. 122 (2002) 態では，天然ホルモンと同様，b-form をとってお a) HOCH 2 (CH 2 ) n CH 2 OH, KOtBu, 110°C, 14 h, n＝0 (88％), n＝1 (94％), and n＝2 (93％), (b) TBDMSCl, imidazole, DMF, n＝0 (93％), n＝1 (92％), and n＝2 (99％), (c) NBS, BaCO3, CCl4, re‰ux, 35 min, n＝0 (71％), n＝1 (74％), and n＝2 (76％), (d) cat. NaOMe, MeOH, n＝0 (95％), n＝1 (96％), and n＝ 2 (99％), (e) TBDMSCl, imidazole, DMF, n＝0 (93％), n＝1 (94％), and n＝2 (85％), (f) cat. Bu4NF, THF, n＝0 (43％), n＝1 (71％), and n＝2 (68％), (g) Zn, NaBH 3 CN, 1-propanol-H 2 O (10：1), 95°C, 45 min, and then, NaBH 4 , n＝0 (71％), n＝1 (72％), and n＝2 (75％), (h) TmCl, DMAP, CH 2 Cl 2 , n＝0 (82％), n＝1 (84％), and n＝2 (92％), (i) LiHMDS, THF, -78°C, rt, n＝0 (92％), n＝1 (99％), and n＝2 (90％), (j) TMSC＝CH, BuLi, BF3 ・OEt 2, THF, -78°C, n＝0 (91％), n＝1 (92％), and n＝2 (94％), (k) K2CO3, MeOH, n＝0 (93％), n＝1 (96％), and n＝2 (63％), (l) TBDMSOTf, 2,6-lutidine, CH2Cl2, 0°C, n＝0 (92％), n＝1 (90％), and n＝2 (80％), (m) cat. (Ph 3 P) 4 Pd, Et 3 N in toluene (1：1), re‰ux, n＝0 (75％), n＝1 (52％), and n＝2 (69％), (n) Bu 4 NF, THF, n＝0 (78％), n ＝1 (61％), and n＝2 (70％).
保護基の変換（d, e, f）後，亜鉛末 NaBH 3 CN で 処理して不飽和ジオール（70）に導いた．70 はエ 
ポキシド（71）を経てエチニル基の導入を行い，72
a) The potency of 1 is normalized to 100. b) Binding a‹nity to bovine thymus VDR, c) Binding a‹nity to calf serum VD binding protein, d ) Cell diŠerentiation was assessed in terms of NBT reductivity. e) Increasing eŠect on serum calcium level in normal rats, f ) Not Tested.
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を経て，A 環前駆体（73）を収率よく合成出来た．
A 環前駆体は，それぞれ常法によりパラジウム触 BuOK と加熱反応させると，Stevens 型転位が起こ 
